| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
2'-Acetylacteoside selectively inhibits aldose reductase (ALR2), the enzyme responsible for the conversion of glucose to sorbitol in the polyol pathway. It also acts as a free radical scavenger.
|
|---|---|
| ln Vitro |
In vitro, 2'-Acetylacteoside inhibits rat lens aldose reductase with potent activity (0.071 μM). It significantly suppresses NADPH/CCl4-induced lipid peroxidation in rat liver microsomes and inhibits free radical-induced hemolysis of red blood cells.
|
| ln Vivo |
In vivo, 2'-Acetylacteoside demonstrates hepatoprotective effects in models of liver injury and neuroprotective effects in models of neurodegeneration. Its aldose reductase inhibitory activity suggests potential for treating diabetic complications.
|
| Enzyme Assay |
Aldose reductase inhibitory activity is measured using purified rat lens aldose reductase enzyme. The enzyme is incubated with DL-glyceraldehyde as substrate and NADPH as cofactor. Inhibition is determined by measuring the decrease in NADPH oxidation spectrophotometrically at 340 nm.
|
| Cell Assay |
Red blood cells or hepatocytes are cultured and exposed to free radical generators or lipid peroxidation inducers in the presence of 2'-Acetylacteoside. Hemolysis inhibition or lipid peroxidation (MDA formation) is measured.
|
| Animal Protocol |
Carbon tetrachloride-induced hepatotoxicity models in rodents are used to evaluate hepatoprotective effects. 2'-Acetylacteoside is administered orally or intraperitoneally, and liver enzyme levels and histopathology are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not extensively characterized. As a glycoside, it is expected to undergo deglycosylation and hepatic metabolism. Further studies are needed to define its absorption and bioavailability.
|
| Toxicity/Toxicokinetics |
Specific toxicity data are limited. The compound is generally considered safe at research doses; however, comprehensive toxicological evaluations are lacking.
|
| References | |
| Additional Infomation |
According to reports, 2-acetyllactoside has been found in Callicarpa purpurea, Pedicularis nigra, and other organisms with available data.
2'-Acetylacteoside is a research compound with no clinical trial or regulatory approval status. It is used primarily as a reference standard and in pharmacological studies of antioxidant, hepatoprotective, and neuroprotective activities. |
| Molecular Formula |
C31H38O16
|
|---|---|
| Molecular Weight |
666.6238
|
| Exact Mass |
666.216
|
| CAS # |
94492-24-7
|
| PubChem CID |
21629996
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
892.2±65.0 °C at 760 mmHg
|
| Flash Point |
283.9±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.664
|
| LogP |
3.04
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
47
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H]([C@H](O[C@H]([C@@H]2OC(=O)C)OCCC3=CC(=C(C=C3)O)O)CO)OC(=O)/C=C/C4=CC(=C(C=C4)O)O)O)O)O
|
| InChi Key |
ALERZNQPBWWLMW-OMRKUVHCSA-N
|
| InChi Code |
InChI=1S/C31H38O16/c1-14-24(39)25(40)26(41)30(43-14)47-28-27(46-23(38)8-5-16-3-6-18(34)20(36)11-16)22(13-32)45-31(29(28)44-15(2)33)42-10-9-17-4-7-19(35)21(37)12-17/h3-8,11-12,14,22,24-32,34-37,39-41H,9-10,13H2,1-2H3/b8-5+/t14-,22+,24-,25+,26+,27+,28-,29+,30-,31+/m0/s1
|
| Chemical Name |
[(2R,3R,4S,5R,6R)-5-acetyloxy-6-[2-(3,4-dihydroxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~150.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5001 mL | 7.5005 mL | 15.0011 mL | |
| 5 mM | 0.3000 mL | 1.5001 mL | 3.0002 mL | |
| 10 mM | 0.1500 mL | 0.7501 mL | 1.5001 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
